




The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 50% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	116,418
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,206
Liabilities, Non-Current	0
Other Assets	1,760
Other Compr. Net Income	-6,489
Other Expenses	991
Other Liabilities	9,937
Other Net Income	-5,403
Other Revenues	14,953
Property and Equipment	0
Research and Development	38,713
Selling, General and Administrative Expense	8,683

Output Variable	Value in 1000 USD
Assets	118,178
Liabilities	30,143
Expenses	48,387
Revenues	14,953
Stockholders Equity	88,035
Net Income	-38,837
Comprehensive Net Income	-42,082
BaseVar	111,776
ECR before LimitedLiability	202%
Economic Capital Ratio	304%